MedTrace Logo

Lipoic Acid for Progressive Multiple Sclerosis (MS)

NCT03161028 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2025-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.

Conditions

Interventions

DRUG

Lipoic acid

1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.

DRUG

Placebo

The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Rebecca I. Spain, MD MSPH · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-17
Primary Completion
2023-12-31
Completion
2024-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161028 on ClinicalTrials.gov